BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference

BrainsWay (NASDAQ: BWAY) will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 8:45 AM ET.

Rhea-AI Summary

BrainsWay (NASDAQ: BWAY) will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 8:45 AM ET.

The presentation offers an investor-facing update; investors and analysts should contact their Needham & Co. representative to request meetings.

Argus Apr 13 session

+3.38% close to close Open Argus

Details

News Market Reaction – BWAY

In the Apr 13 session, BWAY gained 3.38%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights BrainsWay’s participation in the 25th Annual Needham Virtual Healthcare...

Analysis

This announcement highlights BrainsWay’s participation in the 25th Annual Needham Virtual Healthcare Conference, signaling ongoing engagement with the investment community following several operational, clinical, and financial milestones in early 2026. Investors may focus on any incremental commentary around growth, adoption of its depression treatments, and capital allocation. Prior news on earnings, clinical data, and strategic investments provides context for how management might frame its current trajectory and priorities.

Key Figures

Conference edition: 25th Annual Presentation time: 8:45 AM ET Presentation date: April 15, 2026 +5 more

Conference edition

25th Annual

Needham Virtual Healthcare Conference

Presentation time

8:45 AM ET

Needham Virtual Healthcare Conference on April 15, 2026

Presentation date

April 15, 2026

Scheduled conference presentation

Current price

$13.92

Pre-news close vs 52-week range

52-week high

$14.69

BWAY trading 5.24% below high

52-week low

$3.92

BWAY up 255.1% vs 52-week low

200-day MA

$9.16

Shares trading above long-term average

Market cap

$572,472,300

Pre-news valuation snapshot

Historical Context

5 past events · Latest: Mar 26

5 events

1. Mar 26

   FDA-tied investment

   24h Move

   -2.7%

   Milestone-based Neurolief funding following FDA approval of ProlivRx for MDD.

2. Mar 19

   Strategic investment

   24h Move

   +3.6%

   Revenue-based milestone investment in Axis Integrated Mental Health clinics.

3. Mar 11

   Earnings and guidance

   24h Move

   +8.3%

   Strong Q4 and 2025 results with 2026 revenue and EBITDA guidance.

4. Mar 04

   Clinical data update

   24h Move

   +7.4%

   Peer-reviewed data validating SWIFT Deep TMS for faster depression treatment.

5. Feb 25

   Earnings date notice

   24h Move

   +0.2%

   Announcement of timing for Q4 and full-year 2025 results release.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

noninvasive neurostimulation

1 terms

noninvasive neurostimulation medical

"a global leader in advanced noninvasive neurostimulation treatments for mental health"

Noninvasive neurostimulation uses externally applied energy—such as gentle electrical currents, magnetic fields, or focused sound—to change activity in the brain or nervous system without surgery or implants. For investors, it matters because these therapies can open large markets for safer, outpatient treatments with lower procedural risk and easier regulatory paths than surgery, potentially driving recurring device sales, service contracts, and broad adoption like a remote control that adjusts how the brain works.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present at the 25^th Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Wednesday, April 15, 2026.

Please contact your Needham & Co. representative to request a meeting at the conference.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com

Investors:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will BrainsWay (BWAY) present at the Needham Virtual Healthcare Conference?

BrainsWay will present on Wednesday, April 15, 2026 at 8:45 AM ET. According to BrainsWay, management will speak at the 25th Annual Needham Virtual Healthcare Conference and is available for investor meetings via Needham & Co.

How can investors request a meeting with BrainsWay (BWAY) at the April 2026 Needham conference?

Investors should contact their Needham & Co. representative to request a meeting. According to BrainsWay, meeting requests are arranged through Needham & Co., which is coordinating investor and analyst sessions at the virtual event.

What should shareholders expect from BrainsWay's (BWAY) presentation on April 15, 2026?

Expect a management update focused on company developments and strategy for investors and analysts. According to BrainsWay, the presentation will provide an investor-facing overview and opportunity for scheduled meetings via Needham & Co.

Will BrainsWay (BWAY) provide a webcast or replay of the Needham conference presentation?

The press notice does not specify a webcast or replay availability for the presentation. According to BrainsWay, investors should contact their Needham representative to confirm whether a live webcast or replay will be provided after the session.

Is the April 15, 2026 Needham presentation the same as an earnings call for BrainsWay (BWAY)?

No, this is a conference presentation, not an earnings call. According to BrainsWay, management will present at the Needham virtual healthcare conference and investors should request meetings through Needham & Co. for more company details.